J. Goldman & Co LP acquired a new position in Jounce Therapeutics Inc (NASDAQ:JNCE) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $638,000. J. Goldman & Co LP owned approximately 0.16% of Jounce Therapeutics at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the stock. BlackRock Inc. grew its holdings in Jounce Therapeutics by 60.1% in the 4th quarter. BlackRock Inc. now owns 1,161,840 shares of the company’s stock worth $14,812,000 after buying an additional 436,114 shares in the last quarter. Redmile Group LLC grew its holdings in Jounce Therapeutics by 2.6% in the 4th quarter. Redmile Group LLC now owns 980,393 shares of the company’s stock worth $12,500,000 after buying an additional 24,795 shares in the last quarter. Brown Advisory Inc. grew its holdings in Jounce Therapeutics by 3.3% in the 4th quarter. Brown Advisory Inc. now owns 491,529 shares of the company’s stock worth $6,267,000 after buying an additional 15,810 shares in the last quarter. Fosun International Ltd grew its holdings in Jounce Therapeutics by 208.8% in the 3rd quarter. Fosun International Ltd now owns 285,960 shares of the company’s stock worth $4,455,000 after buying an additional 193,350 shares in the last quarter. Finally, Alyeska Investment Group L.P. grew its holdings in Jounce Therapeutics by 43.7% in the 3rd quarter. Alyeska Investment Group L.P. now owns 262,105 shares of the company’s stock worth $4,084,000 after buying an additional 79,683 shares in the last quarter. 90.30% of the stock is owned by institutional investors and hedge funds.
Jounce Therapeutics Inc (NASDAQ JNCE) opened at $24.52 on Friday. Jounce Therapeutics Inc has a one year low of $11.05 and a one year high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Thursday, March 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.25. The firm had revenue of $13.00 million during the quarter, compared to analyst estimates of $14.95 million. Jounce Therapeutics had a negative return on equity of 10.24% and a negative net margin of 22.76%. The firm’s quarterly revenue was down 36.0% on a year-over-year basis. During the same period last year, the company posted $0.05 EPS. equities research analysts forecast that Jounce Therapeutics Inc will post -1.04 EPS for the current year.
A number of brokerages recently issued reports on JNCE. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, January 3rd. Robert W. Baird set a $35.00 price objective on Jounce Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 8th.
In other Jounce Therapeutics news, CEO Richard /Ca/ Murray sold 16,334 shares of the stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $25.10, for a total transaction of $409,983.40. Following the completion of the transaction, the chief executive officer now directly owns 16,334 shares of the company’s stock, valued at approximately $409,983.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Barbara Gayle Duncan sold 4,000 shares of the stock in a transaction on Friday, January 26th. The shares were sold at an average price of $25.00, for a total value of $100,000.00. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at $100,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 58,292 shares of company stock valued at $1,372,403.
TRADEMARK VIOLATION NOTICE: “J. Goldman & Co LP Acquires New Holdings in Jounce Therapeutics Inc (JNCE)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/03/23/j-goldman-co-lp-acquires-new-holdings-in-jounce-therapeutics-inc-jnce.html.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics Inc (NASDAQ:JNCE).
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.